All

Medis Medical Imaging, the leading cardiac imaging software company, announces today the FDA clearance of the latest version of its groundbreaking Medis QFR® in the USA

Terumo Health Outcomes (THO), a division of Terumo Interventional Systems (TIS), and Medis Medical Imaging, a leading cardiac imaging software company, announced today that they have entered into a strategic partnership, in the United States, to enhance cardiovascular care through the utilization of both ePRISM – Terumo’s proprietary clinical decision support platform – and Medis’ Quantitative Flow Ratio (QFR) technology, a non-invasive software solution designed to assess angiography-derived coronary physiology.

Medis’ Quantitative Flow Ratio (QFR®) has been awarded with a Class I recommendation in 3 distinct categories of the 2024 ESC guidelines for the management of patients suffering from chronic coronary syndrome (CCS). This recognition recommends QFR® as a physiology measurement technique next to, and at par with, the traditional wire-based methods. The guidelines also differentiate Medis QFR® from other Angiography-based FFR techniques, which have been called out with a lower IIb/C recommendation, in only one of the 3 categories.

Today, GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, and Medis Medical Imaging, a leading cardiac imaging software company, announced their collaboration aimed at helping advance precision care in the diagnosis and treatment of coronary artery disease (CAD).

We are excited to officially announce the launch of Medis QFR® 3.0, our latest solution designed to streamline your Cath lab workflow for physiology and morphology assessments of intermediate coronary lesions. This new version will bring innovative features, accessibility from anywhere within the hospital network, and a completely new look & feel.